

# Federica Piccioni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7760300/publications.pdf>

Version: 2024-02-01

20  
papers

4,627  
citations

567281

15  
h-index

713466

21  
g-index

24  
all docs

24  
docs citations

24  
times ranked

9660  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. <i>Cell</i> , 2017, 171, 1437-1452.e17.	28.9	2,281
2	Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. <i>Nature Communications</i> , 2018, 9, 5416.	12.8	535
3	A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. <i>Nature</i> , 2013, 504, 138-142.	27.8	401
4	Mutational processes shape the landscape of TP53 mutations in human cancer. <i>Nature Genetics</i> , 2018, 50, 1381-1387.	21.4	334
5	A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. <i>Science</i> , 2019, 365, 599-604.	12.6	265
6	High-throughput Phenotyping of Lung Cancer Somatic Mutations. <i>Cancer Cell</i> , 2016, 30, 214-228.	16.8	171
7	A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer. <i>Cancer Cell</i> , 2015, 27, 397-408.	16.8	150
8	Phenotypic Characterization of a Comprehensive Set of MAPK1 /ERK2 Missense Mutants. <i>Cell Reports</i> , 2016, 17, 1171-1183.	6.4	119
9	Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5974-5989.	7.0	87
10	TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma. <i>Cancer Cell</i> , 2021, 39, 1262-1278.e7.	16.8	49
11	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. <i>Nature Communications</i> , 2019, 10, 2400.	12.8	37
12	An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML. <i>Cancer Discovery</i> , 2022, 12, 432-449.	9.4	32
13	Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 92-104.	8.2	30
14	PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. <i>Nature Communications</i> , 2022, 13, 604.	12.8	22
15	Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer. <i>Nature Communications</i> , 2021, 12, 4789.	12.8	21
16	Pooled Lentiviral Delivery Genetic Screens. <i>Current Protocols in Molecular Biology</i> , 2018, 121, 32.1.1-32.1.21.	2.9	20
17	Comprehensive Mutational Analysis of the BRCA1-Associated DNA Helicase and Tumor-Suppressor FANCF/BACH1/BRIP1. <i>Molecular Cancer Research</i> , 2021, 19, 1015-1025.	3.4	15
18	Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state. <i>Nature Communications</i> , 2022, 13, .	12.8	15

#	ARTICLE	IF	CITATIONS
19	A genome-wide gain-of-function screen identifies CDKN2C as a HBV host factor. Nature Communications, 2020, 11, 2707.	12.8	11
20	Considerations and practical implications of performing a phenotypic CRISPR/Cas survival screen. PLoS ONE, 2022, 17, e0263262.	2.5	4